Source: newswire.ca
Last week Teva (TEVA) announced it had launched a generic version of Allergan's (AGN) blockbuster dry-eye drug Restasis in Canada:
Teva Canada Limited, a subsidiary of Teva Pharmaceutical Industries Ltd., announced the launch of Teva-Cyclosporine® ophthalmic emulsion, 0.05% w/v, a Health Canada approved twice-daily eye drop solution and the first generic version of Restasis® (cyclosporine) in Canada.
Cyclosporine ophthalmic emulsion is indicated for the treatment of moderate to moderately severei aqueous deficient dry eye disease, characterized by moderate to moderately severe: ocular staining, reduction in tear production and fluctuating visual symptoms, such as blurred vision.
Reports suggest Restasis had annual sales in Canada of $46.5 million. The Restasis patents were invalidated in U.S. Federal Court due to obviousness last year. Teva's launch could have implications on the possibility of a generic version of the drug being approved in the U.S.


